PCa Vaccine Followed by Docetaxel Beneficial
ANAHEIM, Calif.—Men with androgen independent prostate cancer (AIPC) who have received initial treatment with sipuleucel-T (Provenge) followed by docetaxel after progression of their disease may have prolonged survival, according to new findings presented here at the American Urological Association annual meeting.